Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

By sjmartinez • February 7, 2023

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023 Feb 5:e14539. doi: 10.1111/nmo.14539. Epub ahead of print. PMID: 36740814.

Tags: abdominal pain, cannabinoid receptor agonists, cannabinoids, Digestive Diseases, Irritable Bowel Syndrome, olorinab, Publications

Thermal Ablation with or without Liver Transplantation for Hepatocellular Carcinoma in Older Adults with Child-Pugh Class A Cirrhosis

McWilliams JP, Ramakrishnan A, Lee EW, Padia SA, Pianka S, Tran S, Lu D, Raman S, Saab S, Shetty A, Agopian V. Thermal Ablation with[...]

Methylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations

Parikh ND, Liu CC, DeMaio M, Yeh AH, Stackpole ML, Li S, Agopian VG, Li W, Zhou XJ, Ni X, Lok AS, Han SB. Methylation[...]

The American Society for Gastrointestinal Endoscopy Technology Status Evaluation Report: endoscopic submucosal dissection

ASGE TECHNOLOGY COMMITTEE; Leung G, Guerrero Vinsard D, Abdi M, Akerman PA, Akshintala VS, Benias PC, Das KK, Desilets DJ, Hanscom M, Mansour NM, Marya[...]